Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1270–1272. doi: 10.1038/sj.bjc.6690203

Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?

A M Gillespie 1, N Siddiqui 2, R E Coleman 1, B W Hancock 1
PMCID: PMC2362241  PMID: 10098770

Abstract

In the UK there are standardized surveillance procedures for gestational trophoblastic disease. However, there are differences in practice between the two treatment centres in terms of definition of persistent gestational trophoblastic disease, prognostic risk assessment and chemotherapeutic regimens. The role of prophylactic chemotherapy for cerebral micrometastatic disease in persistent gestational trophoblastic disease is unclear. We have analysed the outcome of 69 patients with lung metastases who elsewhere might have received prophylactic intrathecal chemotherapy. Of the 69 patients, 67 received intravenous chemotherapy only. The other two patients had cerebral metastases at presentation. One patient who received only intravenous chemotherapy subsequently developed a cerebral metastasis, but this patient's initial treatment was compromised by non-compliance. This experience supports our current policy of not treating patients with pulmonary metastases, without clinical evidence of central nervous system (CNS) involvement, with prophylactic intrathecal therapy. © 1999 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (57.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Athanassiou A., Begent R. H., Newlands E. S., Parker D., Rustin G. J., Bagshawe K. D. Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital. Cancer. 1983 Nov 1;52(9):1728–1735. doi: 10.1002/1097-0142(19831101)52:9<1728::aid-cncr2820520929>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  2. Bagshawe K. D., Harland S. Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer. 1976 Jul;38(1):112–118. doi: 10.1002/1097-0142(197607)38:1<112::aid-cncr2820380120>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  3. Evans A. C., Jr, Soper J. T., Clarke-Pearson D. L., Berchuck A., Rodriguez G. C., Hammond C. B. Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol. 1995 Nov;59(2):226–230. doi: 10.1006/gyno.1995.0013. [DOI] [PubMed] [Google Scholar]
  4. Fisher P. M., Hancock B. W. Gestational trophoblastic diseases and their treatment. Cancer Treat Rev. 1997 Jan;23(1):1–16. doi: 10.1016/s0305-7372(97)90017-7. [DOI] [PubMed] [Google Scholar]
  5. Roberts J. P., Lurain J. R. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol. 1996 Jun;174(6):1917–1924. doi: 10.1016/s0002-9378(96)70229-6. [DOI] [PubMed] [Google Scholar]
  6. Shapiro W. R., Young D. F., Mehta B. M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975 Jul 24;293(4):161–166. doi: 10.1056/NEJM197507242930402. [DOI] [PubMed] [Google Scholar]
  7. Yordan E. L., Jr, Schlaerth J., Gaddis O., Morrow C. P. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol. 1987 Apr;69(4):627–630. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES